May 13, 2009 - NewCardio Inc. this week is introducing the QTinno, an automated analysis of ECGs used to determine cardiac toxicity during drug development, and the Visual3Dx, which generates 3D information from the heart using standard 12-lead ECG data, during Heart Rhythm 2009 in Boston.
The company said it is expected to provide clinicians additional information on the extent and location of damage to the heart caused by a myocardial infarction to improve the speed and accuracy of diagnosis.
Heart Rhythm 2009 takes place May 13-16, 2009 in Boston, MA. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology.
NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.